Overcoming resistance to fulvestrant (ICI182,780) by Downregulating the c-ABL Proto-Oncogene in breast cancer

Molecular Carcinogenesis

Volumn 50, Issue 5, 2011, Pages 383-389

  Zhao, Huajun ^a   Lo, Yuan Hung ^a   Yu, Ling ^b   Wang, Shao Chun ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b ZHEJIANG UNIVERSITY   (China)

Author keywords

Breast cancer; C ABL; Estrogen receptor; Fulvestrant; ICI182,780

Indexed keywords

ABELSON KINASE; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; IMATINIB;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER PATIENT; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN TISSUE; PRIORITY JOURNAL; PROTO ONCOGENE;

ANTINEOPLASTIC AGENTS, HORMONAL; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELL SURVIVAL; DOWN-REGULATION; DRUG RESISTANCE, NEOPLASM; DRUG SYNERGISM; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FEMALE; FLOW CYTOMETRY; HUMANS; PIPERAZINES; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS C-ABL; PYRIMIDINES; RNA INTERFERENCE;

EID: 79953804485     PISSN: 08991987     EISSN: 10982744     Source Type: Journal    
DOI: 10.1002/mc.20721     Document Type: Article

References (34)

1. Shaul Y, Ben-Yehoyada M. Role of c-Abl in the DNA damage stress response. Cell Res 2005; 15: 33-35.
2. Pendergast AM. The Abl family kinases: Mechanisms of regulation and signaling. Adv Cancer Res 2002; 85: 51-100.
3. Plattner R, Pendergast AM. Activation and signaling of the Abl tyrosine kinase: Bidirectional link with phosphoinositide signaling. Cell Cycle 2003; 2: 273-274.
4. Kharbanda S, Yuan ZM, Weichselbaum R, Kufe D. Determination of cell fate by c-Abl activation in the response to DNA damage. Oncogene 1998; 17: 3309-3318.
5. Wang JY. Regulation of cell death by the Abl tyrosine kinase. Oncogene 2000; 19: 5643-5650.
6. Goldman JM, Melo JV. Chronic myeloid leukemia-Advances in biology and new approaches to treatment. N Engl J Med 2003; 349: 1451-1464.
7. Lin J, Sun T, Ji L, et al. Oncogenic activation of c-Abl in non-small cell lung cancer cells lacking FUS1 expression: Inhibition of c-Abl by the tumor suppressor gene product Fus1. Oncogene 2007; 26: 6989-6996.
8. Srinivasan D, Plattner R. Activation of Abl tyrosine kinases promotes invasion of aggressive breast cancer cells. Cancer Res 2006; 66: 5648-5655.
9. Srinivasan D, Sims JT, Plattner R. Aggressive breast cancer cells are dependent on activated Abl kinases for proliferation, anchorage-independent growth and survival. Oncogene 2008; 27: 1095-1105.
10. Sirvent A, Benistant C, Roche S. Cytoplasmic signalling by the c-Abl tyrosine kinase in normal and cancer cells. Biol Cell 2008; 100: 617-631.
11. Wakeling AE, Bowler J. Novel antioestrogens without partial agonist activity. J Steroid Biochem 1988; 31: 645-653.
12. Wakeling AE, Dukes M, Bowler J. A potent specific pure antiestrogen with clinical potential. Cancer Res 1991; 51: 3867-3873.
13. Wakeling AE, Bowler J. Steroidal pure antioestrogens. J Endocrinol 1987; 112: R7-R10.
14. Fawell SE, White R, Hoare S, Sydenham M, Page M, Parker MG. Inhibition of estrogen receptor-DNA binding by the "pure" antiestrogen ICI 164, 384 appears to be mediated by impaired receptor dimerization. Proc Natl Acad Sci USA 1990; 87: 6883-6887.
15. Dauvois S, White R, Parker MG. The antiestrogen ICI 182780 disrupts estrogen receptor nucleocytoplasmic shuttling. J Cell Sci 1993; 106: 1377-1388.
16. Wijayaratne AL, Nagel SC, Paige LA, et al. Comparative analyses of mechanistic differences among antiestrogens. Endocrinology 1999; 140: 5828-5840.
17. Frasor J, Stossi F, Danes JM, Komm B, Lyttle CR, Katzenellenbogen BS. Selective estrogen receptor modulators: Discrimination of agonistic versus antagonistic activities by gene expression profiling in breast cancer cells. Cancer Res 2004; 64: 1522-1533.
18. Osborne CK, Coronado-Heinsohn EB, Hilsenbeck SG, et al. Comparison of the effects of a pure steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J Natl Cancer Inst 1995; 87: 746-750.
19. Howell A. Pure oestrogen antagonists for the treatment of advanced breast cancer. Endocr Relat Cancer 2006; 13: 689-706.
20. Howell A, Robertson JF, Quaresma Albano J, et al. Fulvestrant, formerly ICI 182, 780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002; 20: 3396-3403.
21. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: Results of a North American trial. J Clin Oncol 2002; 20: 3386-3395.
22. Robertson JF, Nicholson RI, Bundred NJ, et al. Comparison of the short-term biological effects of 7alpha-[9-(4, 4, 5, 5, 5-pentafluoropentylsulfinyl)-nonyl]estra-1, 3, 5, (10)-triene-3, 17beta-diol (Faslodex) versus tamoxifen in postmenopausal women with primary breast cancer. Cancer Res 2001; 61: 6739-6746.
23. Zhao H, Ou-Yang F, Chen IF, et al. Enhanced resistance to Tamoxifen by the c-ABL proto-oncogene in breast cancer. Neoplasia (New York, NY) 2010; 12: 214-223.
24. Chou T-C. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacol Rev 2006; 58: 621-681.
25. Ren R, Ye ZS, Baltimore D. Abl protein-tyrosine kinase selects the Crk adapter as a substrate using SH3-binding sites. Genes Dev 1994; 8: 783-795.
26. Johnston SR. New strategies in estrogen receptor-positive breast cancer. Clin Cancer Res 2010; 16: 1979-1987.
27. Miller TW, Perez-Torres M, Narasanna A, et al. Loss of phosphatase and tensin homologue deleted on chromosome 10 engages ErbB3 and insulin-like growth factor-I receptor signaling to promote antiestrogen resistance in breast cancer. Cancer Res 2009; 69: 4192-4201.
28. Frogne T, Benjaminsen R, Sonne-Hansen K, et al. Activation of ErbB3, EGFR and Erk is essential for growth of human breast cancer cell lines with acquired resistance to fulvestrant. Breast Cancer Res Treat 2009; 114: 263-275.
29. McClelland RA, Barrow D, Madden TA, et al. Enhanced epidermal growth factor receptor signaling in MCF7 breast cancer cells after long-term culture in the presence of the pure antiestrogen ICI 182, 780 (Faslodex). Endocrinology 2001; 142: 2776-2788.
30. Fan M, Yan PS, Hartman-Frey C, et al. Diverse gene expression and DNA methylation profiles correlate with differential adaptation of breast cancer cells to the antiestrogens tamoxifen and fulvestrant. Cancer Res 2006; 66: 11954-11966.
31. Oh AS, Lahusen JT, Chien CD, et al. Tyrosine phosphorylation of the nuclear receptor coactivator AIB1/SRC-3 is enhanced by Abl kinase and is required for its activity in cancer cells. Mol Cell Biol 2008; 28: 6580-6593.
32. Osborne CK, Bardou V, Hopp TA, et al. Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer. J Natl Cancer Inst 2003; 95: 353-361.
33. He X, Zheng Z, Song T, et al. c-Abl regulates estrogen receptor [alpha] transcription activity through its stabilization by phosphorylation. Oncogene 2010; 29: 2238-2251.
34. Arnold SF, Obourn JD, Jaffe H, Notides AC. Phosphorylation of the human estrogen receptor on tyrosine 537 in vivo and by src family tyrosine kinases in vitro. Mol Endocrinol 1995; 9: 24-33.